Abstract 5278
Background
We evaluated the impact of tumor type and molecular profiling on overall survival of patients (pts) with cancer referred to Medical Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).
Methods
Pts referred from 1989 to 2017 had molecular testing (for research) of archival tumor tissue collected at the time of diagnosis (stage I-III, 82%; stage IV, 18%). Tumor-specific (e.g. breast, colon) gene panels (45-101 genes) were used to identify pathogenic mutations in clinically relevant genes. Deep sequencing was performed at the Laboratory of Molecular Oncology, Aristotle University of Thessaloniki and HeCOG. Mutation annotation was performed at MD Anderson Cancer Center. All pts received standard-of-care anticancer therapy.
Results
We analyzed 3,211 pts (median age, 58 years; men, 29%) with informative sequencing data. Results by tumor type and molecular pathway are shown in the table. Overall, 1,193 (37%) pts had ≥1 actionable alterations [115 (3.6%) ≥4]. The most common affected pathways were PI3K, RAF/MEK, homologous recombination repair (HRR), and tyrosine kinase; 294 (9.2%) pts had alterations in > 1 pathways. The median follow-up of alive patients is 7.48 years (yrs) (95%CI, 7.36-7.59). Of 3,211 pts, 1,060 (33.01%) have died. The median overall survival is 16.08 yrs (95%CI, 13.25-16.75). Of pts with breast cancer and actionable mutations, the 5-yr survival rates were: stage I-III (n = 501) 88.8%; stage IV (n = 14), 51.1% (p<.0001). Of pts with colorectal cancer and actionable alterations, the 5-yr survival rates were: stage I-III (n = 299), 76.5%; stage IV (n = 50), 15.2% (p<.0001).
Conclusions
Tumor sequencing revealed clinically relevant genomic mutations in several molecular pathways. Prospective clinical trials validating the clinical utility of tumor profiling are warranted.
Clinical trial identification
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Hellenic Cooperative Oncology Group.
Editorial Acknowledgement
NA
Disclosure
All authors have declared no conflicts of interest.Table: 1876P
| Total N | N with actionable alterations | % | Overall Survival | ||
|---|---|---|---|---|---|
| Tumor type | Median, Years (95% CI) | 5-yr OS, % (95% CI) | |||
| Breast | 1,964 | 527 | 27 | NR | 87.8 (85.0-90.7) |
| Colorectal | 533 | 359 | 67 | NR | 68.0 (63.2-73.2) |
| Pancreatic | 188 | 123 | 65 | 0.82 (.65-.98) | - |
| Nasopharyngeal | 144 | 77 | 54 | 8.92 (6.68-NR) | 65.2 (54.7-77.7) |
| Brain | 131 | 24 | 18 | 4.54 (1.69-9.71) | 46.9 (29.9-73.6) |
| Gastric | 101 | 11 | 11 | 4.18 (1.04-NR) | 39.8 (17.8-88.9) |
| Biliary Tract | 80 | 26 | 33 | ND | |
| Ovarian | 70 | 46 | 66 | 3.24 (2.18-5.32) | 36.4 (24.7-53.5) |
| Total | 3,211 | 1,193 | 37 | 13.23 (10.6-NR) | 68.6 (65.9-71.4) |
| Pathway | Total tested | N with actionable alterations | % | ||
| PI3K/AKT/mTOR | 3,211 | 636 | 20 | 16.08 (13.23- NR) | 82.3 (79.3-85.4) |
| MEK/RAF | 3,211 | 459 | 14 | 6.4 (4.08-8.92) | 52.3 (47.7-57.3) |
| HRR | 3,211 | 260 | 8 | 7.84 (5.33-NR) | 56.8 (50.7-63.5) |
| Tyrosine kinase | 3,211 | 161 | 5 | NR | 69.2 (62.0-77.3) |
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract